{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:10:08Z","timestamp":1779210608237,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI165535"],"award-info":[{"award-number":["R01AI165535"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01535-4","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:35:39Z","timestamp":1774384539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19"],"prefix":"10.1038","volume":"6","author":[{"given":"Alaleh","family":"Azhir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1236-1614","authenticated-orcid":false,"given":"Jingya","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-3438","authenticated-orcid":false,"given":"Jiazi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-8806","authenticated-orcid":false,"given":"Shawn N.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-8978","authenticated-orcid":false,"given":"Hossein","family":"Estiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"1535_CR1","doi-asserted-by":"publisher","unstructured":"Adjaye-Gbewonyo, D., Vahratian, A., Cria, G. P. & Bertolli, J. Long COVID in Adults: United States, 2022. (National Center for Health Statistics (U.S.), 2023). https:\/\/doi.org\/10.15620\/cdc:132417.","DOI":"10.15620\/cdc:132417"},{"key":"1535_CR2","doi-asserted-by":"crossref","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","DOI":"10.1056\/NEJMoa2118542"},{"key":"1535_CR3","doi-asserted-by":"crossref","unstructured":"Aggarwal, N. R. et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect. Dis. 23, 696\u2013705 (2023).","DOI":"10.1016\/S1473-3099(23)00011-7"},{"key":"1535_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 183, 554\u2013564 (2023).","journal-title":"JAMA Intern. Med."},{"key":"1535_CR5","doi-asserted-by":"crossref","unstructured":"Jiang, J. et al. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis. J. Infect. 89, 106190 (2024).","DOI":"10.1016\/j.jinf.2024.106190"},{"key":"1535_CR6","doi-asserted-by":"crossref","unstructured":"Durstenfeld, M. S. et al. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J. Med. Virol. 96, e29333 (2024).","DOI":"10.1002\/jmv.29333"},{"key":"1535_CR7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.7326\/M23-1394","volume":"176","author":"GN Ioannou","year":"2023","unstructured":"Ioannou, G. N. et al. Effectiveness of nirmatrelvir-ritonavir against the development of post-COVID-19 conditions among U.S. veterans: a target trial emulation. Ann. Intern. Med. 176, 1486\u20131497 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1535_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/M22-3565","volume":"176","author":"KL Bajema","year":"2023","unstructured":"Bajema, K. L. et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. veterans: target trial emulation studies with one-month and six-month outcomes. Ann. Intern. Med. 176, 807\u2013816 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1535_CR9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamainternmed.2023.5099","volume":"183","author":"KW Fung","year":"2023","unstructured":"Fung, K. W., Baye, F., Baik, S. H. & McDonald, C. J. Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients. JAMA Intern. Med. 183, 1404\u20131406 (2023).","journal-title":"JAMA Intern. Med."},{"key":"1535_CR10","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S1473-3099(24)00217-2","volume":"24","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. Lancet Infect. Dis. 24, 1130\u20131140 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1535_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","volume":"184","author":"LN Geng","year":"2024","unstructured":"Geng, L. N. et al. Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial: the STOP-PASC randomized clinical trial. JAMA Intern. Med. 184, 1024\u20131034 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1535_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28750","volume":"95","author":"MH Chuang","year":"2023","unstructured":"Chuang, M. H. et al. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 95, e28750 (2023).","journal-title":"J. Med. Virol."},{"key":"1535_CR13","doi-asserted-by":"publisher","unstructured":"Wang, F. et al. Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients-A Large-Scale Observational Cohort Study from the RECOVER Initiative. Res sq https:\/\/doi.org\/10.21203\/rs.3.rs-4536807\/v1 (2024).","DOI":"10.21203\/rs.3.rs-4536807\/v1"},{"key":"1535_CR14","doi-asserted-by":"publisher","unstructured":"Shen Y. et al. Assessment of Nirmatrelvir-Ritonavir Effects on Acute and Post-Acute COVID-19 Illness in US Adolescents: Target Trial Emulation. MedRXiv https:\/\/doi.org\/10.1101\/2025.04.02.25324861 (2025).","DOI":"10.1101\/2025.04.02.25324861"},{"key":"1535_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76472-0","volume":"14","author":"FS Sharif-Askari","year":"2024","unstructured":"Sharif-Askari, F. S. et al. Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients. Sci. Rep. 14, 25901 (2024).","journal-title":"Sci. Rep."},{"key":"1535_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19264-5","volume":"24","author":"R Sk Abd Razak","year":"2024","unstructured":"Sk Abd Razak, R. et al. Post-COVID syndrome prevalence: a systematic review and meta-analysis. BMC Public Health 24, 1785 (2024).","journal-title":"BMC Public Health"},{"key":"1535_CR17","doi-asserted-by":"publisher","unstructured":"Azhir, A. et al. Precision phenotyping for curating research cohorts of patients with unexplained post-acute sequelae of COVID-19. Med https:\/\/doi.org\/10.1016\/j.medj.2024.10.009 (2024).","DOI":"10.1016\/j.medj.2024.10.009"},{"key":"1535_CR18","unstructured":"WHO. Coronavirus disease (COVID-19): Post COVID-19 condition. Accessed 2023. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-post-covid-19-condition."},{"key":"1535_CR19","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMsb2408466","volume":"391","author":"EW Ely","year":"2024","unstructured":"Ely, E. W., Brown, L. M. & Fineberg, H. V. National academies of sciences, engineering, and medicine committee on examining the working definition for long covid. Long Covid defined. N. Engl. J. Med. 391, 1746\u20131753 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1535_CR20","doi-asserted-by":"publisher","first-page":"e2238354","DOI":"10.1001\/jamanetworkopen.2022.38354","volume":"5","author":"ZH Strasser","year":"2022","unstructured":"Strasser, Z. H., Greifer, N., Hadavand, A., Murphy, S. N. & Estiri, H. Estimates of SARS-CoV-2 Omicron BA.2 subvariant severity in New England. JAMA Netw. Open 5, e2238354 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1535_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmi.2020.11.028","volume":"27","author":"D Yahav","year":"2021","unstructured":"Yahav, D. et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin. Microbiol. Infect. 27, 315\u2013318 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"1535_CR22","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","volume":"22","author":"JB Soriano","year":"2022","unstructured":"Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102\u2013e107 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1535_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.21105\/joss.00648","volume":"3","author":"A Gasparini","year":"2018","unstructured":"Gasparini, A. comorbidity: An R package for computing comorbidity scores. J. Open Source Softw. 3, 648 (2018).","journal-title":"J. Open Source Softw."},{"key":"1535_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2012","unstructured":"Hainmueller, J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit. Anal. 20, 25\u201346 (2012).","journal-title":"Polit. Anal."},{"key":"1535_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36223-7","volume":"14","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 14, 983 (2023).","journal-title":"Nat. Commun."},{"key":"1535_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1473-3099(24)00171-3","volume":"24","author":"W Zuo","year":"2024","unstructured":"Zuo, W. et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect. Dis. 24, 845\u2013855 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1535_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich, J. The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol. 19, 10\u201319 (2018).","journal-title":"Nat. Immunol."},{"key":"1535_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Sig. Transduct. Target. Ther. 8, 200 (2023).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"1535_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","volume":"71","author":"A Santoro","year":"2021","unstructured":"Santoro, A., Bientinesi, E. & Monti, D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res. Rev. 71, 101422 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1535_CR30","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.cmi.2024.07.023","volume":"30","author":"G Sun","year":"2024","unstructured":"Sun, G., Lin, K., Ai, J. & Zhang, W. The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID\u2019-Author\u2019s reply. Clin. Microbiol. Infect. 30, 1618\u20131619 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"1535_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06052-3","volume":"15","author":"M Berry","year":"2025","unstructured":"Berry, M. et al. Risk of long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. Sci. Rep. 15, 27441 (2025).","journal-title":"Sci. Rep."},{"key":"1535_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/jleuko\/qiac001","volume":"113","author":"MS Islam","year":"2023","unstructured":"Islam, M. S., Wang, Z., Abdel-Mohsen, M., Chen, X. & Montaner, L. J. Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID. J. Leukoc. Biol. 113, 236\u2013254 (2023).","journal-title":"J. Leukoc. Biol."},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"T Greenhalgh","year":"2024","unstructured":"Greenhalgh, T., Sivan, M., Perlowski, A. & Nikolich, J. \u017d Long COVID: a clinical update. Lancet 404, 707\u2013724 (2024).","journal-title":"Lancet"},{"key":"1535_CR34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86002","volume":"12","author":"ZA Sherif","year":"2023","unstructured":"Sherif, Z. A., Gomez, C. R., Connors, T. J., Henrich, T. J. & Reeves, W. B. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 12, e86002 (2023).","journal-title":"Elife"},{"key":"1535_CR35","first-page":"1891","volume":"29","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A. et al. Covid-19 Commission of the Accademia Nazionale dei Lincei Cappuccinelli Pietro 13 Fitzgerald Garrett 14 Bacci Massimo Livi 15 Melino Gennaro 16 Parisi Giorgio 17 Rappuoli Rino 18 19 Rezza Giovanni 20 Vineis Paolo 21. Long Covid: where we stand and challenges ahead. Cell Death Differ. 29, 1891\u20131900 (2022).","journal-title":"Cell Death Differ."},{"key":"1535_CR36","doi-asserted-by":"publisher","first-page":"e0275274","DOI":"10.1371\/journal.pone.0275274","volume":"17","author":"JA Frontera","year":"2022","unstructured":"Frontera, J. A. et al. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: a prospective, observational study. Plos ONE 17, e0275274 (2022).","journal-title":"Plos ONE"},{"key":"1535_CR37","doi-asserted-by":"crossref","unstructured":"Sawano, M. et al. Nirmatrelvir\u2013ritonavir versus placebo\u2013ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. Lancet Infect. Dis. 25, 936\u2013946 (2025).","DOI":"10.1016\/S1473-3099(25)00073-8"},{"key":"1535_CR38","unstructured":"Greifer, N. Weighting for covariate balance in observational studies [R package WeightIt version 0.13.1]. Published online 2022. Accessed July 7, 2022. https:\/\/CRAN.R-project.org\/package=WeightIt."},{"key":"1535_CR39","unstructured":"Greifer, N. Covariate balance tables and plots: a guide to the cobalt package. 2024. Accessed May 31, 2024. https:\/\/cloud.r-project.org\/web\/packages\/cobalt\/vignettes\/cobalt.html."},{"key":"1535_CR40","unstructured":"Arel-Bundock, V., Greifer, N. & Bacher, E. Marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests.; 2024. Accessed May 31, 2024. https:\/\/CRAN.R-project.org\/package=marginaleffects."},{"key":"1535_CR41","unstructured":"Survey: analysis of complex survey samples. Comprehensive R Archive Network (CRAN). Accessed 2022. https:\/\/cran.r-project.org\/web\/packages\/survey\/index.html."},{"key":"1535_CR42","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.18749575","author":"A Azhir","year":"2026","unstructured":"Azhir, A., Cheng, J. & Estiri, H. Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19. Version 1.0.1. Zenodo https:\/\/doi.org\/10.5281\/zenodo.18749575 (2026).","journal-title":"Version 1.0.1. Zenodo"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01535-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01535-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01535-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:40:25Z","timestamp":1779208825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01535-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01535-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}